The above image shows a quantitative rCBV map, automatically generated within the Arterys platform.
August 24, 2020 — Imaging Biometrics, LLC, a subsidiary of IQ-AI Limited and a recognized leader in quantitative imaging analysis for brain tumor diagnosis and treatment, announced it has taken its suite of products online via Arterys’s industry-leading medical AI platform. The products include IB Neuro, the premier magnetic resonance (MR) imaging dynamic susceptibility contrast (DSC) perfusion solution; IB DCE; IB’s Delta T1 mapping algorithm; and IB Diffusion. This non-exclusive agreement allows Arterys’s global customer base to access IB’s solutions for trial and purchase on the Arterys Marketplace. The above image shows a quantitative rCBV map, automatically generated within the Arterys platform According to Arterys CEO John Axerio-Cilies: “ Imaging Biometrics sets a high bar for other medical AI innovators. We’re excited to bring their algorithms online to the Arterys Marketplace and deliver the tremendous clinical value they create to oncologists and cancer patients across North America and Europe.” “We are delighted to make our products available to the doctors at hospitals around the world who are already connected to the Arterys platform and look forward to providing sophisticated imaging solutions to benefit clinicians and their patients,” said Michael Schmainda, CEO of IB. “The automated and proven accuracy of our solutions are immediately available for trial or purchase through the Arterys platform, and we look forward to expanding the use of our solutions to a much larger customer base,” Schmainda added.
Foe more information: www.imagingbiometrics.com
June 19, 2026 
